Medicare Drug Relief: Just Don't Ask Why We Can Afford It Now
"Medicare enrollees to pay 50 percent less for some drugs next year," cheers The Hill . A genuine, if belated, victory for seniors. But notice how they gloss over the inconvenient truth: these 'savings' are mere drops in the bucket compared to the obscene profits Big Pharma extracted for decades, thanks to relentless lobbying against price negotiation. The pharmaceutical industry spent over $375
million on lobbying in 2022 alone ( OpenSecrets.org ), successfully blocking Medicare from negotiating drug prices for years. Why celebrate basic affordability as some grand achievement when it was actively suppressed? We can now 'afford' these savings, perhaps, because the focus has shifted to funding endless conflicts abroad. The same Congress that finally allows Medicare to haggle for lower
drug prices had no problem rubber-stamping billions in military aid without a second thought, often directly after receiving substantial campaign donations from defense contractors and pro-war PACs. For example, Senator X, who voted to approve HR Y – providing $14 billion in aid to [specific country] – received Z from Lockheed Martin PAC in Q3 2023 ( OpenSecrets.org ). Suddenly finding pennies
under the couch for grandma's meds seems less like a policy breakthrough and more like a carefully managed PR move, designed to distract from where the real cash is flowing.